Industry
Biotechnology
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Loading...
Open
0.67
Mkt cap
71M
Volume
2.1M
High
0.75
P/E Ratio
-0.50
52-wk high
2.48
Low
0.60
Div yield
N/A
52-wk low
0.58
Portfolio Pulse from
November 08, 2024 | 5:45 pm
Portfolio Pulse from
November 08, 2024 | 3:00 pm
Portfolio Pulse from
November 08, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
October 11, 2024 | 8:16 pm
Portfolio Pulse from Avi Kapoor
January 16, 2024 | 11:50 am
Portfolio Pulse from Benzinga Newsdesk
January 04, 2024 | 10:27 pm
Portfolio Pulse from Benzinga Newsdesk
December 26, 2023 | 11:56 am
Portfolio Pulse from Benzinga Insights
December 25, 2023 | 5:30 pm
Portfolio Pulse from Benzinga Insights
December 25, 2023 | 1:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.